Related Experiment Video
Updated: Jul 4, 2025
10:15
Utilizing Repetitive Transcranial Magnetic Stimulation to Improve Language Function in Stroke Patients with Chronic Non-fluent Aphasia
Published on: July 2, 2013
17.8K
Are pharmacotherapeutics effective for treating aphasia?
Guadalupe Dávila1,2,3,4, Marcelo L Berthier1,2,4
1Cognitive Neurology and Aphasia Unit, Centro de Investigaciones Médico-Sanitarias, University of Málaga, Málaga, Spain.
Expert Review of Neurotherapeutics
|February 7, 2024
Summary
Pharmacotherapy for aphasia shows limited effectiveness currently. More research is needed to determine optimal drug treatments for communication disorders caused by stroke or neurodegenerative conditions.
Area of Science:
- Neurology
- Speech-Language Pathology
Background:
- Aphasia is a debilitating communication disorder affecting speech, comprehension, reading, and writing.
- It commonly results from stroke or neurodegenerative conditions impacting the left cerebral hemisphere.
- Effective therapeutic strategies are crucial for managing aphasia's impact on daily life.
Purpose of the Study:
- To evaluate the efficacy of current pharmacotherapeutic strategies for treating aphasia.
- To explore how different causes of aphasia might influence treatment outcomes.
- To provide expert perspectives on current and future pharmacotherapy for aphasia.
Main Methods:
- Review and analysis of existing pharmacotherapeutic approaches for aphasia.
- Consideration of aphasia etiology (vascular vs. neurodegenerative) in treatment efficacy.
- Expert opinion synthesis on the current state of pharmacotherapy.
Main Results:
- The effectiveness of current pharmacotherapy for aphasia remains inconclusive.
- Further research is necessary, focusing on language and communication deficits.
- Biomarkers may enhance personalized treatment planning for aphasia patients.
Conclusions:
- Current pharmacotherapy offers no definitive solution for aphasia.
- Future research should prioritize detailed language assessments and biomarker identification.
- Personalized medicine approaches hold promise for improving aphasia treatment.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
193
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
193
01:26Psychosis: Goals of Pharmacotherapy
131
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
131
01:28Drug Therapy
44
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
44
01:24Parkinson's Disease: Treatment
268
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
268
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
675
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
675
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
126
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
126